Erasca Stock

erasca.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $64MM

Erasca is a biotechnology company committed to solving oncology’s hardest problems.

Register To Buy and Sell Shares

For more details on financing and valuation for Erasca, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Erasca’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Erasca.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Gary Yeung
Chief Business Officer
Jonathan Lim MD
Founder and Executive Chairman

Board Members

James Bristol Ph.D
Jonathan Lim MD
Pratik Multani MD
Alexander Casdin

News Highlights

Erasca Brings In $36M More For Series B For Cancer Treatments
Erasca will use the funding to drive corporate development efforts and further advance the company’s in-house drug discovery pipeline.
San Diego’s Erasca Lands $200M In Series B Round 
San Diego-based cancer treatment startup Erasca raised $200 million in a new round of funding, the company announced Monday.
Erasca Raises $200M in Series B Financing | FinSMEs
Erasca, a San Diego, CA-based develper of oncology programs, completed a $200m Series B financing round co-led by Arch Venture Partners and Cormorant Asset Management
Updated on: Mar 4, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.